Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $7.9 million.

  • Amphastar Pharmaceuticals' Depreciation and Depletion rose 884.92% to $7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.8 million, marking a year-over-year increase of 1156.02%. This contributed to the annual value of $28.2 million for FY2024, which is 1207.7% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Depreciation and Depletion stood at $7.9 million, which was up 884.92% from $8.3 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Depreciation and Depletion high stood at $8.3 million for Q2 2025, and its period low was $5.4 million during Q3 2021.
  • Moreover, its 5-year median value for Depreciation and Depletion was $6.3 million (2023), whereas its average is $6.5 million.
  • Data for Amphastar Pharmaceuticals' Depreciation and Depletion shows a peak YoY increase of 2056.83% (in 2021) and a maximum YoY decrease of 277.28% (in 2021) over the last 5 years.
  • Over the past 5 years, Amphastar Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $5.4 million in 2021, then rose by 14.81% to $6.2 million in 2022, then rose by 7.19% to $6.6 million in 2023, then increased by 9.19% to $7.3 million in 2024, then increased by 8.31% to $7.9 million in 2025.
  • Its last three reported values are $7.9 million in Q3 2025, $8.3 million for Q2 2025, and $7.4 million during Q1 2025.